These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30973735)

  • 1. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Asquith CRM; Naegeli KM; East MP; Laitinen T; Havener TM; Wells CI; Johnson GL; Drewry DH; Zuercher WJ; Morris DC
    J Med Chem; 2019 May; 62(9):4772-4778. PubMed ID: 30973735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
    Sakurai MA; Ozaki Y; Okuzaki D; Naito Y; Sasakura T; Okamoto A; Tabara H; Inoue T; Hagiyama M; Ito A; Yabuta N; Nojima H
    PLoS One; 2014; 9(6):e100124. PubMed ID: 24971999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors.
    Asquith CRM; Tizzard GJ; Bennett JM; Wells CI; Elkins JM; Willson TM; Poso A; Laitinen T
    ChemMedChem; 2020 Jul; 15(13):1200-1215. PubMed ID: 32358915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.
    Asquith CRM; Laitinen T; Bennett JM; Godoi PH; East MP; Tizzard GJ; Graves LM; Johnson GL; Dornsife RE; Wells CI; Elkins JM; Willson TM; Zuercher WJ
    ChemMedChem; 2018 Jan; 13(1):48-66. PubMed ID: 29072804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma.
    Asquith CRM; Maffuid KA; Laitinen T; Torrice CD; Tizzard GJ; Crona DJ; Zuercher WJ
    ChemMedChem; 2019 Oct; 14(19):1693-1700. PubMed ID: 31424613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships.
    Asquith CRM; Laitinen T; Bennett JM; Wells CI; Elkins JM; Zuercher WJ; Tizzard GJ; Poso A
    ChemMedChem; 2020 Jan; 15(1):26-49. PubMed ID: 31675459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).
    Asquith CRM; Berger BT; Wan J; Bennett JM; Capuzzi SJ; Crona DJ; Drewry DH; East MP; Elkins JM; Fedorov O; Godoi PH; Hunter DM; Knapp S; Müller S; Torrice CD; Wells CI; Earp HS; Willson TM; Zuercher WJ
    J Med Chem; 2019 Mar; 62(5):2830-2836. PubMed ID: 30768268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
    Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
    PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
    Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
    Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
    Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.
    Li DD; Lv PC; Zhang H; Zhang HJ; Hou YP; Liu K; Ye YH; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(16):5012-22. PubMed ID: 21763148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase.
    Martinez-Gualda B; Saul S; Froeyen M; Schols D; Herdewijn P; Einav S; De Jonghe S
    Eur J Med Chem; 2021 Mar; 213():113158. PubMed ID: 33497888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
    Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
    J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
    Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
    Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 4-arylaminoquinazolines bearing
    Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
    Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
    Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
    Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
    Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.